Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error
The recall of Ramipril 10mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market share in the cardiovascular segment. Portfolio teams must closely monitor the situation to assess potential impacts on sales and develop strategies to mitigate reputational damage.
Signal
Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error
Company
Crescent Pharma Limited
Category
Strategy
Therapeutic Area
Cardiovascular / ACE Inhibitor
Action
Monitor
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The recall of Ramipril 10mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market share in the cardiovascular segment. Portfolio teams must closely monitor the situation to assess potential impacts on sales and develop strategies to mitigate reputational damage.
Why it matters
The recall of Ramipril 10mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market share in the cardiovascular segment. Portfolio teams must closely monitor the situation to assess potential impacts on sales and develop strategies to mitigate reputational damage.
What changed
Safety Signal
Analysis
Crescent Pharma Limited is recalling a batch of Ramipril 10mg Capsules due to a potential manufacturing error.
The recall of Ramipril 10mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market share in the cardiovascular segment. Portfolio teams must closely monitor the situation to assess potential impacts on sales and develop strategies to mitigate reputational damage.
Monitor for updates on the recall process and any regulatory actions taken by health authorities.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.